Immuvera Therapeutics today announced the appointment of Marie-Paul Lachaud, DVM, as Head of Clinical Operations, further strengthening the company’s capabilities as it advances Nebumet in veterinary oncology.

Dr. Lachaud brings extensive experience from the animal health sector, including clinical development, study oversight and registration strategy across companion animal therapeutics. Her background includes leadership roles in veterinary pharmaceutical development, management of international clinical programs, and long-standing work with clinical and regulatory pathways in animal health.

Prior to joining Immuvera, Dr. Lachaud worked as a consultant to the veterinary pharmaceutical industry, supporting development programs and registration activities in Europe and internationally. Earlier in her career, she served as Director Animal Health, Europe at ICON Clinical Research, where she supervised global, international and local preclinical and clinical studies for major animal health companies. She also co-founded PROTOCOLE, which has been publicly described as the first European veterinary consultancy and contract research organization focused on clinical drug development and regulatory affairs.

At Immuvera, Dr. Lachaud will lead clinical operations planning and execution, support study design and oversight, and contribute to the company’s regulatory development path as Nebumet moves toward the next stage of clinical advancement.

“We are very pleased to welcome Marie-Paul to Immuvera,” said Jørund Sollid, CEO of Immuvera Therapeutics. “She brings rare depth in veterinary clinical development and a strong track record across study execution, sponsor collaboration and registration-oriented development. Her experience is highly relevant as we prepare for pivotal clinical work and continue building Immuvera around Nebumet.”

“I am pleased to join Immuvera at an important stage in the company’s development,” said Marie-Paul Lachaud. “Nebumet represents an innovative approach in veterinary oncology, and I look forward to supporting the team in advancing its clinical development.”

About Immuvera Therapeutics
Immuvera Therapeutics is a Norwegian veterinary oncology company developing inhaled immunotherapies for metastatic cancer in dogs. Its lead product candidate, Nebumet, is being developed as an off-the-shelf inhaled immunotherapy to address lung metastases.